Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 3

2(40.0%)

Phase 2

1(20.0%)

5Total

N/A(2)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06140485Phase 3Unknown

A Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients With Type II Diabetes Mellitus

Role: lead

NCT06141200Phase 3Unknown

NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial

Role: lead

NCT05343767Not ApplicableCompleted

Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus

Role: lead

NCT05347329Not ApplicableCompleted

A Clinical Trial to Investigate the Efficacy and Safety of Tongkat Ali Maca Plus

Role: lead

NCT05343780Phase 2Completed

Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NASH

Role: lead

All 5 trials loaded